BuybackAug 5, 2026, 08:33 AM
Propanc Biopharma Completes First $500K Tranche of Share Buyback
AI Summary
Propanc Biopharma, Inc. announced the completion of the first $500,000 tranche of its share repurchase program within 30 days of its commencement. The company stated its belief that its shares are significantly undervalued, especially as it progresses towards a world-first Phase 1b, First-In-Human study for 40-45 advanced cancer patients in Australia. Propanc intends to continue the buyback program, emphasizing its commitment to reflecting shareholder equity.
Key Highlights
- Completed the first tranche of its share repurchase program.
- First tranche amounted to $500,000.
- Achieved the first tranche within 30 days of commencing the program.
- Company believes it is significantly undervalued.
- Progressing towards a Phase 1b, First-In-Human study for 40-45 advanced cancer patients.
- Clinical study will be rolled out nationally in Australia.
- PRP is considered a first-in-class therapy for metastatic cancer.
Price Impact
More from PPCB